ACAM2000天花疫苗在部署军人中的前瞻性安全性监测研究
本研究前瞻性观察部署美军人员接种ACAM2000天花疫苗后的心肌心包炎及严重皮肤神经事件发生率,比较接种组与未接种组。共14667人提供初始数据,接种组心肌心包炎粗发生率为5.7/1000,未接种组为3.2/1000,调整OR为1.3(95%CI 0.6-2.6),无显著增加,多数病例为亚临床。
要点
- 接种组心肌心包炎粗发生率5.7/1000,未接种组3.2/1000,调整OR 1.3(95%CI 0.6-2.6)。
- 心肌心包炎风险增加无统计学显著性,且绝大多数为亚临床病例。
- 未报告严重或重度神经或皮肤不良事件。
核心结论
- 在经严格筛查的年轻健康军人中,ACAM2000接种与心肌心包炎风险轻度非显著增加相关(调整OR 1.3,未调整OR 1.8),除7例外均为亚临床。
研究设计与样本
- 前瞻性观察性队列研究,计划入组至多15000名ACAM2000接种者(队列1)和至多5000名符合接种条件但未接种者(队列2)。
- 初始及10(6-17)天后收集数据和标本,疑似心肌心包炎病例由盲法独立审查委员会裁定。
- 采用逻辑回归模型控制年龄、种族、性别和运动方案,计算调整OR。
主要发现
- 14667人提供初始数据(队列1 10825人,队列2 3842人),12110人按方案完成第二次访视(队列1 8945人,队列2 3165人)。
- 125人(队列1 111人,队列2 14人)转诊裁定,检出54例亚临床心肌心包炎、5例疑似心肌炎、1例确诊心肌炎、1例疑似心包炎。
- 未调整心肌心包炎发生率:队列1为5.7/1000(95%CI 4.3-7.5),队列2为3.2/1000(95%CI 1.7-5.8)。
- 未调整和调整OR分别为1.8(95%CI 0.9-3.6)和1.3(95%CI 0.6-2.6)。
临床怎么用
- 在接种ACAM2000前应进行筛查,关注心肌心包炎风险,尤其对年轻健康军人群体。
- 接种后应监测心肌心包炎相关症状,尽管多数为亚临床,仍需警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare rates of myopericarditis, severe and serious dermatological or neurological events, and other adverse events in deploying US military personnel who received or did not receive ACAM2000® (Smallpox [Vaccinia] Vaccine, Live) vaccine and to evaluate potential risk factors for development of myopericarditis. METHODS: Prospective observational cohort study enrolling up to 15,000 ACAM2000 recipients (Cohort 1) and up to 5000 persons otherwise eligible for ACAM2000 vaccination but not vaccinated due to recency of vaccination or characteristics of their contacts (Cohort 2). Data and specimens were collected initially and 10 (6-17) days later. Those with clinical or laboratory evidence of possible myopericarditis were referred for further evaluation and adjudication by a blinded independent review committee. The adjusted odds ratio for myopericarditis was determined by a logistic regression model controlling for age, race, gender, and exercise regimen. RESULTS: 14,667 subjects provided initial data and specimens (Cohort 1, 10,825; Cohort 2, 3842); 12,110 (Cohort 1, 8945; Cohort 2, 3165) completed Visit 2 per-protocol. A total of 125 (Cohort 1, 111; Cohort 2, 14) were referred for myopericarditis adjudication, yielding 54 (Cohort 1, 44, Cohort 2, 10) subclinical myopericarditis, 5 suspected myocarditis, 1 confirmed myocarditis, and 1 suspected pericarditis. Unadjusted myopericarditis rates were: Cohort 1, 5.7/1000 (95% CI, 4.3-7.5); Cohort 2, 3.2/1000 (95% CI, 1.7-5.8). Unadjusted and adjusted odds ratios for myopericarditis were 1.8 (95% CI: 0.9-3.6) and 1.3 (95% CI: 0.6-2.6), respectively. One hundred seventeen subjects (1.1%) in Cohort 1 and 13 (0.3%) in Cohort 2 experienced at least 1 serious adverse event. No instances of serious and severe neurological or dermatological adverse events were reported. CONCLUSIONS: In this carefully screened, generally young and healthy service-member population, ACAM2000 vaccination was associated with modest non-significant increases in the risk of myopericarditis (adjusted OR, 1.3; unadjusted OR, 1.8); all but seven cases were subclinical. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT00928577.
引用
- Faix DJ, Gordon DM, Perry LN, et al. Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine. 2020. PMID: 32967791. doi:10.1016/j.vaccine.2020.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。